Federal Register / Vol. 62, No. 18 / Tuesday, January 28, 1997 / Notices 4071

A recombinant DNA clone that

encodes high-affinity cell surface

receptors for laminin, a glycoprotein

component of basement membranes,

offers an important tool for studying a

variety of normal and abnormal cell

processes including tumor metastases.

These laminin receptors have been

shown to inhibit metastases. These

recombinant receptors can be used in

diagnostic methods, to assess the

content of laminin receptor mRNA, and

to determine the pattern of laminin

receptor genes in different tissue and

tumor cell populations. (portfolio:

Cancer—Research Materials; Cancer—

Diagnostics, Mab based)

Dated: January 17, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–2062 Filed 1–27–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Geographical and Statistical

Modeling of Exposure to OCCs/DAHs in LI

and Breast Cancer and the Environment on

Long Island.

Date: January 31, 1997.

Time: 2:30 p.m.

Place: Teleconference, Executive Plaza

North, Room 643B, 6130 Executive

Boulevard, Bethesda, MD 20892.

Contact Person: Robert Browning, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 643B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7929.

Purpose/Agenda: To evaluate and review

grant applications.

This notice is being published less

than 15 days prior to the meeting due

to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

The meeting will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. Applications and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material and

personal information concerning

individuals associated with the

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control.)

Dated: January 21, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–1979 Filed 1–27–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of

Planning Group Meeting

Notice is hereby given that the

National Cancer Institute will hold a

public meeting of a Planning Group

which will assist NCI in establishing a

Director’s Consumer Liaison Group

(DCLG). The Planning Group meeting

will begin at 8:30 a.m. on March 13,

1997 and will end at 1:00 p.m. on March

14, 1997 at the Holiday Inn (Bethesda,

MD). All sessions of the Planning Group

meeting are open to the public.

However, seating is limited and will be

on a first-come, first served basis.

A temporary DCLG Planning Group of

NCI staff and consumer-advocates was

formed to help in establishing the

DCLG. The purpose of the DCLG is to:

(1) Help develop and establish

processes, mechanisms, and criteria for

identifying appropriate consumeradvocates to serve on a variety of

program and policy advisory

committees responsible for advancing

the mission of the NCI; (2) serve as a

primary forum for discussing issues and

concerns and exchanging viewpoints

that are important to the broad

development of NCI programmatic and

research priorities, e.g., the

development of the annual Bypass

Budget; and (3) establish and maintain

strong collaborations between NCI and

the cancer advocacy community to

reach common goals. The DCLG,

consisting of approximately 15

consumer-advocates who are involved

in cancer advocacy and/or voluntary

organizations, will meet several times a

year. NCI anticipates that the activities

and initiatives developed by NCI, in

conjunction with the DCLG, will serve

as models for consumer participation.

Nominations for the members of the

DCLG will be solicited from the cancer

advocacy community. The first meeting

of the DCLG is planned for late June

1997. A notice of the date and location

of this meeting will be published in the

Federal Register at a later date.

The objectives of the Planning Group

are to: (1) define the initial role of the

DCLG; and (2) define the DCLG

membership solicitation process, as well

as the criteria, categories, and rating

system to identify and rank potential

members of the DCLG. Development of

criteria for membership on the DCLG

will include identification of categories

of members needed to ensure balance

and diversity of representation. To

identify DCLG members, the process

selected by the Planning Group to

announce and invite submission of

names of consumer-advocates to serve

on the DCLG will be followed.

Nominees will be screened for eligibility

according to a set of criteria and

categories developed by the DCLG

Planning Group. Consumer-advocates

who are on the Planning Group will be

unable to serve as members of the DCLG

in its first year of operation, but their

organizations may be represented by

another individual.

To provide input to the Planning

Group, members of advocacy or

voluntary organizations related to

cancer are invited to submit eligibility

criteria and categories that could be

used to identify individuals who could

serve on the DCLG. These criteria and

categories will be used to help the

Planning Group to develop the process

for identifying DCLG members.

Submissions on criteria and categories

should be mailed to Ms. Fran Oscar at

Palladian Partners, 7315 Wisconsin

Avenue, Suite 440W, Bethesda, MD

20814, or sent to her by FAX to (301)

986–5047 or by E-mail to

palladianp@.aol.com. They must be

received no later than 5:00 p.m. (EST)

on February 15, 1997 to be included in

the materials provided to the Planning

Group prior to the meeting. Submissions

received after that date and time will be

accepted, but may not be included in

the materials considered by the

Planning Group members at the March

13–14 meeting. All submission must be

accompanied by the following

information: (1) Name and address of

individual making the submission; and

(2) name and address of cancer

advocacy or voluntary organization with

which they are affiliated.

Individuals who plan to attend the

meeting and need special assistance,

such as sign language interpretation or

other special accommodations, should

call Ms. Elaine Lee, Office of Liaison

Activities, NCI at (301) 496–0644 or

contract her by FAX (301) 402–2594 or

E-mail (leee@od.nci.nih.gov) in advance

of the meeting, by February 15, 1997.

For additional information, contact Ms.

Lee.